Retatrutide, a experimental dual agonist of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor , is showing promising outcomes in preliminary clinical trials . Current https://bookmarkfavors.com/story7061155/retatrutide-emerging-research-and-possible-therapeutic-applications